N.J. biotech seeks to raise $57.5M by going public

09/19/2013 | American City Business Journals · Xconomy

Aerie Pharmaceuticals, a Bedminster, N.J.-based developer of eye disease treatments, could bring in as much as $57.5 million in an initial public offering. The company plans to use the money to create a sales force and advance its experimental glaucoma drug AR-13324 through a Phase III trial and the drug PG324 through a midstage trial.

View Full Article in:

American City Business Journals · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA